Phocas Financial Corp’s PTC Therapeutics PTCT Stock Holding History

Phocas Financial Corp’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.77M	Buy	46,170 +26,295	+132%	+$1.9M	0.52%	82
2026 Q1	$1.35M	Sell	19,875 -5,607	-22%	-$397K	0.21%	121
2025 Q4	$1.94M	Sell	25,482 -11,752	-32%	-$854K	0.25%	114
2025 Q3	$2.29M	Buy	+37,234	New	+$1.94M	0.3%	106
2023 Q4	–	Sell	-64,701	Closed	-$1.45M	–	184
2023 Q3	$1.45M	Sell	64,701 -15,996	-20%	-$595K	0.21%	118
2023 Q2	$3.28M	Sell	80,697 -21,203	-21%	-$1.04M	0.45%	92
2023 Q1	$4.94M	Buy	101,900 +32,035	+46%	+$1.46M	0.71%	60
2022 Q4	$2.67M	Sell	69,865 -71	-0.1%	-$2.95K	0.38%	101
2022 Q3	$3.51M	Buy	+69,936	New	+$3.43M	0.54%	82

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Phocas Financial Corp's PTCT Position: Q2 2026 in Review

Phocas Financial Corp increased its PTC Therapeutics (PTCT) stake by 132% in Q2 2026, buying an estimated $1.9M and bringing the position to 46,170 shares worth $3.77M. The position accounts for 0.52% of the portfolio, ranked #82.

Phocas Financial Corp first reported a position in PTCT in Q3 2022 and has held it in 9 quarters since. The position peaked at $4.94M in Q1 2023. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Phocas Financial Corp held 46,170 shares of PTC Therapeutics worth $3.77M as of Q2 2026.
Phocas Financial Corp bought 26,295 PTC Therapeutics shares in Q2 2026, an estimated $1.9M.
PTC Therapeutics made up 0.52% of Phocas Financial Corp's portfolio in Q2 2026, its #82 holding.
Phocas Financial Corp first reported a position in PTC Therapeutics in Q3 2022 and has held it in 9 quarters since.
Phocas Financial Corp's PTC Therapeutics position peaked at $4.94M in Q1 2023.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Phocas Financial Corp's 13F filing for Q2 2026, filed 31 Jul 2026.